![Jump to content [Access key 'm']](/siteware/cleardot.gif){kind=small}
Site map
- Home
- Our Company
- Company Overview
- Business Strategy
- Research and Development Pipeline
- People
- Board of Directors
- Management Team
- Scientific Advisory Board
- Alliances and Collaborations
- R&D
- Programs
- Oncology Programs
- Sapacitabine (CYC682)
- Seliciclib (CYC202)
- CYC116 Aurora Kinase & VEGFR2 Inhibitor
- Other Programs
- Science and Technology
- Cell Cycle in Cancer
- Drug Discovery & Development Approach
- Clinical Trials
- Sapacitabine (CYC682)
- Seliciclib (CYC202)
- CYC116
- Publications
- Investors
- Corporate Governance
- Board of Directors
- Committee Composition
- Management Team
- Stock Information
- Stock Price NASDAQ
- News
- Press Releases
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
- 1997
- SEC Filings
- Analysts
- Corporate Presentations
- 2007
- 2008
- Annual Reports
- 2007
- 2006
- Calendar of Events
- Request Investor Pack
- Careers
- Employment
- Current Vacancies
- Site Services
- Site Map
- Disclaimer
- Privacy
- Contact Us
- Thank you
- Search
- Alerting Service
